Search the web
Welcome, Guest
[Sign Out, My Account]
Morningstar_Inc.

Saturday, May 28 2016 5:53pm ET - U.S. Markets Closed.
Industry Center - Drug Manufacturers - Major
Industry Center > Drug Manufacturers - Major
More On This Industry
Summary
·News
·Leaders & Laggards
· Company Index
·Industry Browser
Related Industries
· Biotechnology
· Diagnostic Substances
· Drug Delivery
· Drug Manufacturers - Other
· Drug Related Products
· Drugs - Generic
· REIT - Retail
Top Industries
·Auto Manufacturers - Major
·Biotechnology
·Business Software & Services
·Chemicals - Major Diversified
·Communication Equipment
·Conglomerates
·Diversified Computer Systems
·Diversified Investments
·Diversified Utilities
·Drug Manufacturers - Major
·Electric Utilities
·Food - Major Diversified
·Industrial Metals & Minerals
·Major Airlines
·Major Integrated Oil & Gas
·Money Center Banks
·Property & Casualty Insurance
·Semiconductor - Broad Line
·Telecom Services - Domestic
·Tobacco Products, Other
Complete Industry List...
Morningstar Inc.
In-depth Company Dossier Reports on over 7,500 publicly traded U.S. companies. Click here for your free report.
  
Industry Market Summary
Drug Manufacturers - Major
Composite Value: 1054.5
Today's Change: +0.48%
S&P 500: +0.43%
chart for
[Drug Manufacturers - Major (^YHOh783)]
Drug Manufacturers - Major News
Merck Receives Positive CHMP Opinion for ZEPATIER™ (elbasvir and grazoprevir) in the European Union
Fri 7:46 am ET (Business Wire)
Merck , known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending approval of ZEPATIER™ , an investigational, once-daily, fixed-dose combination tablet for the treatment of chronic hepatitis C virus in adult patients.
AbbVie's HUMIRA® (adalimumab) Receives CHMP Positive Opinion to Treat Certain Forms of Non-Infectious Uveitis, a Disease that Can Severely Impact Vision - (PR Newswire)
AstraZeneca's Fulvestrant Met Its Primary Endpoint as First-Line Treatment in a Phase III Trial for HR+ Advanced Breast Cancer - (Business Wire)
More News on Drug Manufacturers - Major: Latest News,
Industry Top Performers
Intraday Price Performance% ChangeMarket Cap
More Top Intraday Price Performers...
Market Capitalization% ChangeMarket Cap
PFIZER [PFZ.L] +0.76% $20687.2 B
GLAXOSMITHKLINE [GSK.L] -0.31% $7078.1 B
JOHNSON & JOHNSON [JNJ.MX] -0.18% $5726.5 B
ASTRAZENECA [AZN.L] +0.27% $5074.6 B
PFIZER [PFE.MX] +0.19% $3869.8 B
More Top Companies by Market Cap...
More Top Performers: by Valuation, by Growth, by Financial Strength
Industry Calendar
Upcoming Events
Date Co Event
05/27/16 RX.V Biosyent Inc Q1 2016 Earnings Release
07/26/16 LLY Eli Lilly and Co Q2 2016 Earnings Release
07/27/16 BAYN.DE Bayer AG Q2 2016 Earnings Release
More Upcoming Events...
Recent Events
Date Co Event
05/26/16 FDC.NS FDC LIMITED upside earnings surprise (+8.04%)
05/25/16 GLAXO.NS GLAXOSMITHKLINE PHARMACEUTICALS downside earnings surprise (-22.06%)
05/24/16 CIPLA.NS CIPLA LIMITED downside earnings surprise (-77.75%)
More Recent Events...
  
Locate Industry by Company
Enter Symbol:
Industry Statistics
Market Capitalization:44,472B
Price / Earnings:20.2
Price / Book:5822.3
Net Profit Margin (mrq):21.4%
Price To Free Cash Flow (mrq):-52.9
Return on Equity:24.6%
Total Debt / Equity:85.0
Dividend Yield:3.5%
View Industry Browser
Community Spotlight
Most Active Boards
Board Popularity
GSK
SGP
BDSI
Unusually Active Boards
Board Variance
BDSI
SGP
JNJ

RSS Feeds

Add headlines to your
personalized My Yahoo Page
( About My Yahoo and RSS )

Drug Manufacturers - Major Headlines
More Finance RSS Feeds


Copyright © 2016 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Industry information © 2016 Morningstar, Inc. All Rights Reserved. Company information © 2016 Capital IQ All Rights Reserved. Quotes and other information supplied by independent providers identified on the Yahoo Finance partner page. S&P 500 index provided by Comstock. All rights reserved. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Capital IQ, Morningstar, CSI and exchanges) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Yahoo site, a user agrees not to redistribute the information found therein.

Questions or Comments?